HPV Vaccination Resources

Mar. 2025Important Notices

To help protect against cancers later in life, it is important to increase HPV vaccination rates in adolescents starting at age 9. According to the Centers for Disease Control and Prevention, HPV vaccination is routinely recommended at age 11 or 12, but the vaccine can be given starting at age 9.1 The Pennsylvania Cancer Coalition cites the following potential benefits of initiating the HPV vaccine series at age 9.2

  • More time to complete the series by age 13
  • Strong immune response to the HPV vaccine
  • Increased likelihood of vaccinating before the first HPV exposure
  • Fewer questions about sexual activity by parents and guardians
  • Fewer requests for only vaccines that are “required” for school
  • Fewer shots per visit
  • Highly acceptable to systems, providers, and parents

You can use these resources from the American Cancer Society National HPV Vaccination Roundtable and Pennsylvania Cancer Coalition to support your efforts to begin recommending HPV vaccination at age 9:

As your partner in care, UPMC Health Plan is also here as a resource for you. If you have questions about this effort or ways your practice can help achieve goals around it, please contact your physician account executive or call Provider Services at 1-866-918-1595.

UPMC Health Plan does not practice medicine or exercise control over the methods or professional judgments by which providers render medical services to members. Nothing in these materials should be construed to supersede or replace the clinical judgment of a provider. 


1Centers for Disease Control and Prevention. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. Aug. 16, 2019. Accessed March 24, 2025. cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm

2Pennsylvania Cancer Coalition. Start recommending HPV vaccination at age 9. March 2025.


Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates